Psoriasis (Auckland, N.Z.)最新文献

{"title":"Low Serum Adiponectin May Identify MASLD as a Comorbidity in Patients with Moderate-to-Severe Psoriasis.","authors":"Luisa Ackermann, Andreas Geier, Matthias Goebeler, Andreas Kerstan, Janik Fleissner","doi":"10.2147/PTT.S634886","DOIUrl":"10.2147/PTT.S634886","url":null,"abstract":"<p><strong>Purpose: </strong>Psoriasis is an independent risk factor for metabolic dysfunction-associated steatotic liver disease (MASLD), a condition that frequently remains undetected in clinical routine diagnostics. We investigated whether routine laboratory parameters as well as serum adipokines and cytokines differ between psoriasis patients with and without concurrent MASLD.</p><p><strong>Patients and methods: </strong>In this single-center retrospective study, patients with moderate-to-severe plaque psoriasis hospitalized between 2015 and 2024 were analyzed. MASLD was defined as hepatic steatosis (imaging and/or medical records) in conjunction with at least one cardiometabolic risk factor, after exclusion of other liver disease and harmful alcohol use. Serum adipokines and cytokines were quantified by bead-based multiplex assays. Groups were compared by Mann-Whitney U and Fisher exact tests; associations were assessed by Spearman correlation and BMI-adjusted multiple linear regression.</p><p><strong>Results: </strong>Forty-two psoriasis patients with MASLD (MASLD +) were compared with 17 without (MASLD -). MASLD + patients showed higher BMI (median 32.9 vs 26.7 kg/m², p=0.005), serum ALT (p=0.049), total cholesterol (p=0.007), LDL cholesterol (p=0.023), and CRP (p=0.038), and suffered more frequently from dyslipidemia (p=0.028). Serum adiponectin was significantly lower in MASLD + patients (12.3 vs 22.1 µg/mL, p=0.042), whereas leptin, resistin, adipsin, and all cytokines analyzed did not differ. Adiponectin inversely correlated with BMI (ρ=-0.29, p=0.046); after adjustment for BMI, the group difference was attenuated.</p><p><strong>Conclusion: </strong>In moderate-to-severe psoriasis, concurrent MASLD is characterized by a metabolically adverse profile and reduced serum adiponectin. As the difference is partly explained by BMI, adiponectin warrants prospective evaluation as a candidate marker of concurrent MASLD.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"16 ","pages":"634886"},"PeriodicalIF":5.2,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13644558/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149139590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Four Weeks of Biologic Treatment are Sufficient to Normalize Blunted HPA-Axis Activity and Significantly Improve Psychological Burden in Patients with Psoriasis.","authors":"Frederik Krefting, Stefanie Hölsken, Paraskevi Savvidou, Lukas Sollfrank, Carl Maximilian Thielmann, Jan-Malte Placke, Maurice Moelleken, Lennart Ocker-Serger, Lea Jessica Albrecht, Joachim Dissemond, Sven Benson, Manfred Schedlowski, Wiebke Sondermann","doi":"10.2147/PTT.S616359","DOIUrl":"https://doi.org/10.2147/PTT.S616359","url":null,"abstract":"<p><strong>Purpose: </strong>Psoriasis is associated with substantial psychological burden and dysregulation of endocrine pathways, including the hypothalamic-pituitary-adrenal (HPA) axis. Although biologic therapies improve skin disease, early changes in psychological burden and HPA-axis activity remain insufficiently characterized. This study addresses this scientific gap.</p><p><strong>Patients and methods: </strong>This prospective observational study analyzed data from n = 50 patients with moderate-to-severe psoriasis who were assessed at baseline and after 4 weeks of biologic therapy, and from n = 50 matched healthy controls evaluated at baseline. Primary psychological outcomes were depressive symptoms, anxiety, and perceived stress, measured using Beck's Depression Inventory (BDI), the State-Trait Anxiety-Depression Inventory (STADI), and the Perceived Stress Scale (PSS). Plasma cortisol levels were analyzed in a sampling-time-matched subgroup of n = 25 patients and n = 25 healthy controls.</p><p><strong>Results: </strong>At baseline, patients with psoriasis showed pronounced psychological distress compared with healthy controls, including higher depressive symptoms, state and trait anxiety, state and trait depression, and perceived stress. After 4 weeks of biologic treatment, patients with psoriasis showed significant improvements in BDI, STADI state anxiety, STADI trait anxiety, and PSS scores (all p ≤0.002). By week 4, BDI scores, trait anxiety, and perceived stress were no longer different between patients and controls according to Bonferroni-adjusted tests. Baseline plasma cortisol in patients with psoriasis was lower than in controls (p =0.015) and increased significantly after 4 weeks (p =0.008), no longer differing from healthy controls (p =0.839). Concurrently, PASI decreased from 16.9 to 7.2 after 4 weeks of biologic therapy (p <0.001).</p><p><strong>Conclusion: </strong>After only 4 weeks of biologic therapy, patients with psoriasis showed marked improvement in psychological burden, and plasma cortisol shifted from a reduced baseline level toward the range observed in healthy controls, consistent with early normalization of HPA-axis activity.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"16 ","pages":"616359"},"PeriodicalIF":5.2,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13632688/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149119857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causal Relationship Between Psoriatic Arthritis and Coronary Heart Disease: A Mendelian Randomization and Bioinformatics Analysis.","authors":"Xietian Yin, Shichao Zhao, Wei Huang, Mai Zhang, Shiwen Zhan, Zhiqin Ye, Zhangkui Tan, Qiping Lu","doi":"10.2147/PTT.S623994","DOIUrl":"10.2147/PTT.S623994","url":null,"abstract":"<p><strong>Objective: </strong>Psoriatic arthritis (PsA) often coexists with coronary heart disease (CHD). We integrated Mendelian randomization (MR), bioinformatics and reverse network pharmacology to dissect their causality, biomarkers, candidate therapeutics and transcription factors (TFs).</p><p><strong>Methods: </strong>With PsA and CHD GWAS statistics, five MR methods including inverse variance weighted (IVW), weighted mode, weighted median, simple mode, MR Egger were used to assess causality, followed by sensitivity analyses. We analyzed the differentially expressed genes (DEGs) from the PsA and CHD GEO datasets and identified co-DEGs through intersection. GO, KEGG and GeneMANIA analyses elucidated their functions and pathways. We screened therapeutic candidates through DSigDB and reverse network pharmacology, and mined co-DEGs-related TFs from TRRUST.</p><p><strong>Results: </strong>The MR analysis revealed genetically predicted PsA confers increased CHD risk (IVW, OR = 1.098, 95% CI 1.016, 1.187, <i>p</i> = 0.018), whereas reverse MR showed no causal effect of CHD on PsA. Our study revealed 71 DEGs from GSE61281 (PsA) and 1116 DEGs from GSE66360 (CHD). The seven intersecting co-DEGs participated in immune recruitment, migration, and inflammatory activation, linked to NF-κB, TLR, and CLR pathways. The drug prediction analysis indicated that prednisone, tretinoin, fumaric acid, adenosine, fenofibrate, and herbal medicines including <i>Salvia miltiorrhiza Bunge, Conioselinum anthriscoides</i> \"Chuanxiong\",<i> Achyranthes bidentata Blume</i>, along with herbal ingredients like kaempferol and naringenin, might treat the comorbidities. Notably, these candidates were computational predictions requiring subsequent experimental validation. TF prediction for BCL2A1, CSTA and LY96 highlighted related TFs.</p><p><strong>Conclusion: </strong>Our study validates the PsA-CHD correlation and identifies shared novel molecular characteristics. It offers genetic evidence supporting a causal effect of PsA on CHD (not definitive clinical causation). The predicted drugs and herbs can become candidate targets for subsequent research. Due to the limitations of the European population and the limited sample size of public transcriptome data, our findings require further external validation.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"16 ","pages":"623994"},"PeriodicalIF":5.2,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13614339/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149066703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrasound Renal Stress Test Assessment in Moderate-to-Severe Psoriasis: A Pilot Study.","authors":"Stefano Piaserico, Roberto Mazzetto, Jacopo Tartaglia, Marco Bogo, Christian Ciolfi, Federico Nalesso","doi":"10.2147/PTT.S622097","DOIUrl":"10.2147/PTT.S622097","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is increasingly recognized as a systemic inflammatory disease and has been associated with chronic kidney disease. Whether psoriasis is also linked to subclinical impairment in renal microcirculation remains unclear.</p><p><strong>Objective: </strong>To assess renal functional reserve (RFR) in patients with moderate-to-severe psoriasis using the renal stress test (RST).</p><p><strong>Methods: </strong>Fifty-one consecutive adults with psoriasis and 35 age- and sex-matched controls underwent RST. Renal resistive index (RRI) was measured by Doppler ultrasound in an interlobular renal artery at baseline and after abdominal compression with a fluid-filled bag corresponding to 10% of body weight. Intrarenal resistive index variation (IRRIV) was calculated as the percentage difference between baseline and stress values.</p><p><strong>Results: </strong>Patients with psoriasis showed a lower IRRIV than controls (median 13.8% [10.7-18.6] vs 23.1% [17.8-25.0]; p<0.001). IRRIV differed significantly across controls and Psoriasis Area and Severity Index (PASI) severity strata (p<0.001), but post hoc pairwise comparisons showed that this difference was driven by the comparison between controls and psoriasis patients, with no significant difference between severity strata. In multivariable analysis, psoriasis remained independently associated with lower IRRIV.</p><p><strong>Limitations: </strong>This was a single-center pilot study with a limited sample size.</p><p><strong>Conclusion: </strong>Moderate-to-severe psoriasis was associated with impaired renal functional reserve, suggesting subclinical renal microcirculatory dysfunction. Larger studies are needed to confirm these findings and define their clinical relevance.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"16 ","pages":"622097"},"PeriodicalIF":5.2,"publicationDate":"2026-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13599797/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149042586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhibiting HuR-Mediated mRNA Stabilization Attenuates Psoriasis-Like Inflammation in Preclinical Models.","authors":"Dalila Paladino, Claudio G Atene, Martina Paganin, Elisabetta Palazzo, Marika Quadri, Alessandra Marconi, Dorian Tace, Lorenza Lazzari, Elena Trombetta, Michela Roccuzzo, Marta Tornese, Alessia Faiulo, Luca Reggiani Bonetti, Marco Manfredini, Gianluca Nazzaro, Angelo V Marzano, Daniela Arosio, Pierfausto Seneci, Alessandro Provenzani, Vito G D'Agostino, Roberta Lotti","doi":"10.2147/PTT.S627030","DOIUrl":"10.2147/PTT.S627030","url":null,"abstract":"<p><strong>Purpose: </strong>Psoriasis is a chronic inflammatory skin disease characterized by hyperproliferative keratinocytes and activated Th17/Th1 lymphocytes, which sustain a self-perpetuating cycle by releasing pro-inflammatory cytokines. The RNA-binding protein (RBP) Human Antigen R (HuR) stabilizes many of these cytokine mRNAs, contributing to disease progression. This study aims to investigate the role of the HuR protein in psoriasis and modulate its activity to develop novel therapeutic strategies.</p><p><strong>Patients and methods: </strong>We evaluated the effects of Human Antigen R (HuR) silencing on psoriatic markers in both patient-derived keratinocytes and lymphocytes. Furthermore, we identified novel HuR targets within a psoriatic context using enhanced Cross-Linking and ImmunoPrecipitation sequencing (eCLIP-seq) in psoriasis-like HaCaT cells. Finally, we investigated the pharmacological effects of the TM11, a Tanshinone-mimic (TM) molecule, in an in vivo mouse model and an ex vivo 3D human skin model.</p><p><strong>Results: </strong>Studies on HuR function in HaCaT cells and in patient-derived primary keratinocytes and lymphocytes, demonstrated that keratinocyte proliferation and lymphocyte activation and differentiation are both dependent on HuR. In psoriatic-like HaCaT cells, eCLIP-seq data identified novel psoriatic-related HuR targets, and its mRNA-stabilizing activity was confirmed. Treatment with TM11, that competes with HuR-mRNA binding, reduced keratinocyte proliferation and psoriasis proteins (Cyclin B, Survivin, S100A7, eFABP), and almost suppressed T-cell activation (CD25⁺CD69⁺) and Th17/Th1 cytokine production. In vivo, TM11 reduced psoriasis-like symptoms in Imiquimod-treated mice, reducing Psoriasis Area and Severity Index (PASI) scores, systemic inflammation and histological alterations. In ex vivo InflammaSkin^® models, TM11 restored epidermal morphology, decreased Ki-67 positive cells and lowered IL17AF and IFN-γ secretion.</p><p><strong>Conclusion: </strong>Overall, these findings highlight HuR as a key driver of psoriasis pathogenesis and provide preclinical evidence that pharmacological modulation of HuR activity, by TM11 treatment, could provide a conceptual therapeutic rationale for psoriasis, potentially contributing to the reduction of keratinocyte hyperproliferation and immune activation while favouring the restoration of skin homeostasis. However, further preclinical and clinical validation will be required to establish its translational feasibility.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"16 ","pages":"627030"},"PeriodicalIF":5.2,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13592426/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149019143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secukinumab and Adalimumab on Bone Health in Psoriasis: A Longitudinal Cohort Study.","authors":"Chongli Yu, Zhenkai Zhao, Dengfa Gao, Jianfeng Fan, Yuxin Qiu, Shuya Zhang, Nan Wu, Chengxin Li, Houchen Lyu, Rui Wang","doi":"10.2147/PTT.S626214","DOIUrl":"10.2147/PTT.S626214","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is associated with skeletal comorbidities, but longitudinal data on bone outcomes in patients receiving biologics are limited.</p><p><strong>Objective: </strong>To compare bone mineral density (BMD) and bone turnover marker trajectories among patients with psoriasis initiating secukinumab or adalimumab.</p><p><strong>Methods: </strong>In this retrospective cohort study, 364 patients with psoriasis who initiated secukinumab or adalimumab between 2021 and 2024 were screened. Of these, 50 patients had a valid baseline dual-energy X-ray absorptiometry (DXA) assessment and at least one post-baseline DXA assessment, contributing 128 DXA assessments in total. In addition, 91 patients had a valid baseline bone-turnover-marker measurement and at least one post-baseline measurement, contributing 265 biomarker observations. Longitudinal trajectories were compared using covariate-adjusted, overlap-weighted linear mixed-effects models including treatment, time, and treatment-by-time interaction terms.</p><p><strong>Results: </strong>Secukinumab was associated with more favorable lumbar spine (β = 0.039; 95% CI, 0.019-0.059; P<0.001) and femoral neck BMD trajectories (β = 0.022; 95% CI, 0.005-0.039; P=0.012). Secukinumab was also associated with increased osteocalcin and reduced CTX trajectories, whereas P1NP did not differ significantly.</p><p><strong>Limitations: </strong>Limitations include the retrospective single-center design, modest sample size, treatment imbalance, surrogate outcomes, and potential residual confounding.</p><p><strong>Conclusion: </strong>Compared with adalimumab, secukinumab was associated with more favorable longitudinal BMD trajectories and a bone turnover profile consistent with increased formation and reduced resorption in patients with psoriasis.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"16 ","pages":"626214"},"PeriodicalIF":5.2,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13577176/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148978423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening for Eating Disorders in Psoriasis Patients: A Multicenter Cross-Sectional Study.","authors":"Laura Calabrese, Maria Letizia Musumeci, Romina Ortega, Federico Bardazzi, Lidia Sacchelli, Matteo Megna, Giuseppe Micali","doi":"10.2147/PTT.S635458","DOIUrl":"10.2147/PTT.S635458","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is widely recognized as a systemic inflammatory condition associated with numerous comorbidities. Among these, eating disorders (ED) and ED-related behavior, defined as restrictive or dysfunctional attitudes toward food, have been increasingly reported in patients with psoriasis. Aim of our study was to evaluate the prevalence of ED-related symptoms in psoriasis patients with excess body weight and to explore their association with body mass index (BMI) across the overweight and obese ranges.</p><p><strong>Methods: </strong>A multicenter, cross-sectional study was conducted on adult patients with psoriasis and BMI ≥25 kg/m². ED-related symptoms were assessed using the Binge Eating Scale (BES ≥17) and Eating Attitudes Test-26 (EAT-26). Screening positivity required a positive result in at least one questionnaire. Patients were stratified into four BMI categories. Variables were compared using standard non-parametric tests, and logistic regression assessed predictors of screening positivity.</p><p><strong>Results: </strong>A total of 104 patients were included. Overall, 13 patients (12.5%) tested positive in at least one questionnaire. No statistically significant differences in the proportion of screening-positive patients were observed across the BMI categories or between the overweight and obese groups. Similarly, the mean BES and EAT-26 scores did not differ significantly between groups. Logistic regression analysis confirmed that BMI was not a significant predictor of ED-related screening positivity (OR = 0.942, 95% CI: 0.813-1.091). Spearman's analysis showed no significant correlation between BMI and BES scores (<i>ρ</i> = 0.031, p = 0.753) but a weak negative correlation between BMI and EAT-26 scores (<i>ρ</i> = -0.211, p = 0.032).</p><p><strong>Conclusion: </strong>Approximately one in eight psoriasis patients with excess body weight screened positive for ED-related symptoms. BMI category was not a predictor of ED-screening positivity. The weak negative correlation between BMI and restrictive eating attitudes indicates that dysfunctional eating behaviors may be more pronounced in patients with milder excess weight.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"16 ","pages":"635458"},"PeriodicalIF":5.2,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13549389/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148908223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adalimumab Reduces Epicardial Adipose Tissue in Psoriasis: A Post Hoc Analysis of a Randomized Placebo-Controlled Clinical Trial.","authors":"Ravi Ramessur, Faradia Kernizan, Ehsan Ranjbar, Nehal N Mehta, Abass Alavi, Daniel B Shin, Gianluca Iacobellis, Joel M Gelfand","doi":"10.2147/PTT.S628498","DOIUrl":"10.2147/PTT.S628498","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is associated with increased epicardial adipose tissue (EAT), a metabolically active fat depot in direct contact with the myocardium, and a mediator of coronary artery disease and atrial fibrillation. The effects of psoriasis treatments on EAT are largely unknown. We conducted a post hoc analysis of the Vascular Inflammation in Psoriasis (VIP) trial (NCT01553058, NCT01866592).</p><p><strong>Methods: </strong>VIP compared, in a 1:1:1 randomized manner, placebo (n=27), adalimumab (n=31), and phototherapy (n=28) from baseline to week 12, with all subjects then receiving adalimumab for 52 weeks. EAT volume was quantified from CT imaging at baseline, week 12, and week 52, with concurrent assessment of clinical variables and metabolic and inflammatory biomarkers.</p><p><strong>Results: </strong>At baseline (N=86), EAT volume was positively correlated with age (r = 0.51, p= 2.44 × 10^-), body mass index (r = 0.48, p= 2.01×10^-6), and weight (r = 0.52, p= 3.17 × 10^-), and with inflammatory biomarkers GlycA (r = 0.27, p= 9.48×10^-3), C-reactive protein (r = 0.25, p= 9.94×10^-3), and IL-6 (r = 0.23, p= 0.02). Over 12 weeks, adalimumab treatment reduced EAT volume (mean change -11.9 cm³, p=0.04; baseline mean EAT 183.1 cm³), with no improvement observed in the placebo or phototherapy groups. When compared with the placebo and phototherapy arms combined, adalimumab was associated with a greater reduction in EAT at week 12 (between-group difference -13.9 cm³, p=0.03). The reduction in EAT was not significantly associated with changes in weight or PASI. No additional reduction in EAT was observed after 52 weeks of adalimumab treatment.</p><p><strong>Conclusion: </strong>Adalimumab was associated with an early reduction in EAT that was not significantly correlated with changes in weight or psoriasis activity. These findings indicate treatment-specific effects on a high-risk cardiac fat depot and suggest that TNF inhibition may influence cardiac adiposity relevant to cardiovascular disease.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"16 ","pages":"628498"},"PeriodicalIF":5.2,"publicationDate":"2026-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540581/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148889603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Psoriasis on Patient Well-Being Across Life Stages: A Cross-Sectional Survey (Inpsight Working Group).","authors":"Esteban Daudén, Pablo De la Cueva, Isabel Belinchón, Fernando Gallardo, Pablo Coto, Ricardo Ruiz-Villaverde, José Luís Poveda, Esther Ramirez, Elena Colominas, Sandra Ros, Santiago Alfonso, Dámaris López-Pérez, Marta Comellas","doi":"10.2147/PTT.S603931","DOIUrl":"10.2147/PTT.S603931","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is a chronic disease with a multidimensional impact that extends beyond skin symptoms, affecting physical, emotional, social well-being and satisfaction with care. This study aims to explore the perceived self-reported impact of psoriasis on patients' well-being across different life stages and to identify risk and protective factors associated with well-being over time.</p><p><strong>Methods: </strong>A cross-sectional observational study was conducted using an electronic questionnaire administered to adult patients with psoriasis and healthcare professionals involved in psoriasis management. Patients retrospectively self-reported the perceived impact of psoriasis on overall well-being and its physical, emotional, social, and treatment-related domains across consecutive 10-year life stages. Both patients and healthcare professionals evaluated perceived risk and protective factors for well-being.</p><p><strong>Results: </strong>A total of 53 patients and 54 healthcare professionals completed the questionnaire. Most patients (90.6%) reported psoriasis had negatively affected their general well-being at some point during the disease course, with the physical (90.6%) and emotional (88.7%) domains being the most impacted. The highest perceived burden was reported between 31 and 40 years of age. Better reported symptom control was associated with lower perceived impairment in well-being. Key risk factors included affected body areas (95.3%), comorbidities (93.5%), and disease severity (89.7%), whereas appropriate treatment (96.3%), adequate medical care (93.5%), and a positive physician-patient relationship (89.7%) were identified as protective factors.</p><p><strong>Conclusion: </strong>These exploratory findings suggest that the self-reported perceived impact of psoriasis on well-being varies across life stages and is strongly influenced by symptom control and holistic disease management. These findings support a longitudinal, patient-centered approach to optimize long-term well-being.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"16 ","pages":"603931"},"PeriodicalIF":5.2,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13429117/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148665272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Effectiveness of Upadacitinib in Difficult-to-Treat Psoriatic Arthritis: A 104-week Real-World Clinical and Ultrasound Study.","authors":"D Graceffa, F Sperati, M C Fargnoli, N Cameli, A Pacifico, I Demofonte, V Lora","doi":"10.2147/PTT.S611459","DOIUrl":"10.2147/PTT.S611459","url":null,"abstract":"<p><strong>Background: </strong>Difficult-to-treat psoriatic arthritis (D2T PsA) represents a challenging condition characterized by inadequate response to multiple therapeutic agents. Real-world data on the effectiveness of Janus kinase inhibitors (JAKi) in this population remain limited.</p><p><strong>Objective: </strong>To evaluate the effectiveness, safety, and treatment persistence of Upadacitinib (UPA) in patients with D2T PsA using both clinical and ultrasound assessments.</p><p><strong>Patients and methods: </strong>This observational retrospective study included patients with PsA who failed at least one conventional DMARD and two biologic DMARDs with different mechanisms of action. All patients received UPA 15 mg once daily as monotherapy. Treatment persistence was assessed over 140 weeks, while effectiveness data were collected at four time points following baseline (12, 24, 48, and 104 weeks). Clinical measures included: PASI; cDAPSA score; swollen/tender joints count; assessment of enthesitis and dactylitis; VAS scores for disease activity/pain; HAQ. At baseline and during the follow-up, ultrasound imaging was performed according to the EULAR-OMERACT ultrasound score.</p><p><strong>Results: </strong>Twenty-five patients were enrolled. After 140 weeks, treatment persistence was 68%. A rapid and sustained improvement in disease activity was observed, with mean cDAPSA decreasing from 27.88±5.2 at baseline to 12.04±8.17 at week 12 and 4.88±4.54 at week 52. At one year, 70.6% of patients achieved complete remission and 23.6% low disease activity. Ultrasound findings confirmed the clinical improvement, with a significant reduction in the EULAR-OMERACT score and complete resolution of enthesitis after one year of treatment. Most patients (94.1%) maintained complete remission or low disease activity up to week 104. Skin condition also improved significantly as demonstrated by the marked reduction in PASI score which decreased from a baseline value of 2.22 ± 2.62 to 0.21 ± 0.36 after 52 weeks of treatment. The safety profile was favorable, with mild lipid and CPK abnormalities being the most common adverse events.</p><p><strong>Conclusion: </strong>In this real-world cohort of patients with D2T PsA, UPA demonstrated sustained clinical and ultrasound effectiveness with a favorable safety profile and good long-term treatment persistence.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"16 ","pages":"611459"},"PeriodicalIF":5.2,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13401931/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148594964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}